1. Home
  2. SWIN vs CVKD Comparison

SWIN vs CVKD Comparison

Compare SWIN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWIN
  • CVKD
  • Stock Information
  • Founded
  • SWIN 2017
  • CVKD 2022
  • Country
  • SWIN Hong Kong
  • CVKD United States
  • Employees
  • SWIN N/A
  • CVKD N/A
  • Industry
  • SWIN
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • SWIN
  • CVKD Health Care
  • Exchange
  • SWIN Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • SWIN 214.1M
  • CVKD 29.5M
  • IPO Year
  • SWIN 2023
  • CVKD 2023
  • Fundamental
  • Price
  • SWIN $3.93
  • CVKD $10.54
  • Analyst Decision
  • SWIN
  • CVKD Strong Buy
  • Analyst Count
  • SWIN 0
  • CVKD 1
  • Target Price
  • SWIN N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • SWIN 208.1K
  • CVKD 27.7K
  • Earning Date
  • SWIN 08-21-2025
  • CVKD 08-11-2025
  • Dividend Yield
  • SWIN N/A
  • CVKD N/A
  • EPS Growth
  • SWIN N/A
  • CVKD N/A
  • EPS
  • SWIN N/A
  • CVKD N/A
  • Revenue
  • SWIN $3,316,000.00
  • CVKD N/A
  • Revenue This Year
  • SWIN $29.79
  • CVKD N/A
  • Revenue Next Year
  • SWIN $54.60
  • CVKD N/A
  • P/E Ratio
  • SWIN N/A
  • CVKD N/A
  • Revenue Growth
  • SWIN N/A
  • CVKD N/A
  • 52 Week Low
  • SWIN $1.16
  • CVKD $5.70
  • 52 Week High
  • SWIN $4.40
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • SWIN 62.05
  • CVKD 37.37
  • Support Level
  • SWIN $3.70
  • CVKD $11.25
  • Resistance Level
  • SWIN $3.99
  • CVKD $11.88
  • Average True Range (ATR)
  • SWIN 0.35
  • CVKD 0.77
  • MACD
  • SWIN -0.03
  • CVKD -0.03
  • Stochastic Oscillator
  • SWIN 93.02
  • CVKD 2.95

About SWIN Solowin Holdings

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: